Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2011

01-12-2011 | Original Paper

Diversity of axin in signaling pathways and its relation to colorectal cancer

Authors: Nighat Parveen, Mahboob Ul Hussain, Arshad A. Pandith, Syed Mudassar

Published in: Medical Oncology | Special Issue 1/2011

Login to get access

Abstract

Colorectal cancer is one of the commonest cancers in western world, while majority of cases of CRC are sporadic, a significant minority occurs as a result of inherited genetic mutations. Various studies have demonstrated that tumorigenesis of colon arises as a result of accumulation of multiple genetic alterations targeting the single signal transduction pathway. Genetic alteration of axin has been implicated in different cancers including colorectal cancers. Axin being a multidomain protein interacts with multiple proteins and acts as major scaffold protein in signaling pathways like c-jun/SAPK, TGF-β, and Wnt. In different signaling pathways, axin utilizes different domains and hence exerts distinct roles.
Literature
1.
Cancer. World Health Organization. February 2006. Retrieved on 2007-05-24.
2.
Colorectal cancer facts and figures 2008.
3.
4.
Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871–6.PubMedCrossRef
5.
Dhar GM, Shah GN, Naheed B, Hafiza. Epidemiological trend in the distribution of cancer in Kashmir Valley. J Epidenmiol Conmnm Health. 1993;47:290–2.CrossRef
6.
Khuroo MS, Zargar SA, Mahajan R, Banday MA. High incidence of oesophageal and gastric cancer in Kashmir in a population with special personal and dietary habits. Gut. 1992;33(1):11–5.PubMedCrossRef
7.
O’brien MJ, Winawer SJ, Zauber AG. Flat adenomas in the National Polyp Study: is there increased risk forhigh-grade dysplasia initially or during surveillance? Clin Gastroenterol Hepatol. 2004;2:905–11.PubMedCrossRef
8.
Zauber AG, O’Brien MJ, Winawer SJ. On finding flat adenomas: is the search worth the gain? Gastroenterology. 2002;122:839–40.PubMedCrossRef
9.
Paula MC, Harold F. The genetics of CRC. Ann Intern Med. 2002;137:603–12.
10.
Zeng L, Fagotto F, Zhang T, et al. The mouse fused locus encodes Axin, an inhibitor of the Wnt signalling pathway that regulates embryonic axis formation. Cell. 1997;90:181–92.PubMedCrossRef
11.
Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci USA. 2004;101:2882–7.PubMedCrossRef
12.
Yamamoto H, Kishida S, Uochi T, et al. Axil, a member of the Axin family, interacts with both glycogen synthase kinase 3 beta and beta-catenin and inhibits axis formation of Xenopus embryos. Mol Cell Biol. 1998;18:2867–75.PubMed
13.
Mai M, Qian C, Yokomizo A, et al. Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23–q24. Genomics. 1999;55:341–4.PubMedCrossRef
14.
Liu W, Dong X, Mai M, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet. 2000;26:146–7.PubMedCrossRef
15.
Dong X, Seelan RS, Qian C, et al. Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet. 2001;93:26–8.PubMedCrossRef
16.
Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–9.PubMedCrossRef
17.
Hart MJ, los Santos DR, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with th APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;573–581.
18.
Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17:1371–84.PubMedCrossRef
19.
Fagotto F, Jho E, Zeng L, Kurth T, Joos T, Kaufmann C, Costantini F. Domains of Axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization. J Cell Biol. 1999;145:741–56.PubMedCrossRef
20.
Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem. 1999;274:3439–45.PubMedCrossRef
21.
Julius MA, Schelbert B, Hsu W, Fitzpatrick E, Jho E, Fagotto F, Costantini F, Kitajewski J. Domains of Axin and disheveled required for interaction and function in Wnt signaling. Biochem Biophys Res Commun. 2000;276:1162–9.PubMedCrossRef
22.
Kishida S, Yamamoto H, Hino SI, Ikeda S, Kishida M, Kikuchi A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate -catenin stability. Mol Cell Biol. 1999;19:4414–22.PubMed
23.
Li L, Yuan H, Weaver CD, Mao J, Farr GH III, Sussman DJ, Jonkers J, Kimelman D, Wu D. Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 1999;18:4233–40.PubMedCrossRef
24.
Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H, Fryer LG, Hutchinson L, Fry MJ, Dale TC. Interaction of Axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 1999;18:2823–35.PubMedCrossRef
25.
Schwarz-Romond T, Asbrand C, Bakkers J, Ku¨hl M, Schaeffe HJ, Huelsken RJ, Behrens J, Hammerschmidt M, Birchmeier W. The ankyrin repeat protein Diversin recruits Casein kinase Iε to the beta-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev. 2002;16:2073–84.PubMedCrossRef
26.
Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y, Kikuchi A, Miyazono K, Kato M. Axin facilitates Smad3activation in the transforming growth factor signaling pathway. Mol Cell Biol. 2001;21:5132–41.PubMedCrossRef
27.
Itoh K, Krupnik VE, Sokol SY. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. Curr Biol. 1998;8:591–4.PubMedCrossRef
28.
Sakanaka C, Weiss JB, Williams LT. Bridging of beta-catenin and glycogen synthase kinase-3beta by Axin and inhibition of beta-catenin-mediated transcription. Proc Natl Acad Sci USA. 1998;95:3020–3.PubMedCrossRef
29.
Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet. 2004;74:1043–50.PubMedCrossRef
30.
Yu HM, Jerchow IB, Sheu TJ, Liu B, Costantin Fi, Puzas JE, Birchmeier W, Hsu W. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development. 2005;132:1995–2005.PubMedCrossRef
31.
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24:245–50.PubMedCrossRef
32.
Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21:4863–71.PubMedCrossRef
33.
Aulehla A, Wehrle C, Brand-Saberi B, Kemler R, Gossler A, Kanzler B, Herrmann BG. Wnt3a plays a major role in the segmentation clock controlling somitogenesis. Dev Cell. 2003;4:395–406.PubMedCrossRef
34.
Jho E, Zhang T, Domon C, Joo C-K, Freund J-N, Costantini F. Wnt/-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002;22:1172–83.PubMedCrossRef
35.
Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem. 2002;277:21657–65.PubMedCrossRef
36.
Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 2002;22:1184–93.PubMedCrossRef
37.
Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA. 2001;98:14973–8.PubMedCrossRef
38.
Anderson CB, Neufeld KL, White RL. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc Natl Acad Sci USA. 2002;99:8683–8.PubMedCrossRef
39.
Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 2003;1:E10.PubMedCrossRef
40.
Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L, Wu D. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001;7:801–9.PubMedCrossRef
41.
Wehrli M, Dougan ST, Caldwell K, O’Keefe L, Schwartz S. Vaizel D: arrow encodes an LDLreceptor-related protein essential for Wingless signaling. Nature. 2000;407:527–30.PubMedCrossRef
42.
Tolwinski NS, Wehrli M, Rives A, Erdeniz N, DiNardo S, Wieschaus E. Wg/Wnt signal canbe transmitted through arrow/LRP5, 6 and Axin independently of Zw3/GSK-3ß activity. Dev Cell. 2003;4:407–18.PubMedCrossRef
43.
Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, Kikuchi A. Axin, anegative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of ß-catenin. J Biol Chem. 1998;273:10823–6.PubMedCrossRef
44.
Hart MJ, de los Santos R, Albert IN, Polakis P. Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK-3β. Curr Biol. 1998;8:573–81.PubMedCrossRef
45.
Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, Akiyama T. Axin, an inhibitor of the Wnt signaling pathway, interacts with β-catenin, GSK-3β and APC and reduces the β-catenin level. Genes Cells. 1998;3:395–403.PubMedCrossRef
46.
Rubinfeld B, Tice DA, Polakis P. Axin-dependent phosphorylation of the adenomatous polyposis coli protein mediated by casein kinase IÂ. J Biol Chem. 2001;276:39037–45.PubMedCrossRef
47.
Shiomi K, Uchida H, Keino-Masu K, Masu M. Ccd1, a novel protein with a DIX domain, is a positive regulator in the Wnt signaling during zebrafish neural patterning. Curr Biol. 2003;13:73–7.PubMedCrossRef
48.
Kadoya T, Kishida S, Fukui A, Hinoi T, Michiue T, Asashima M, Kikuchi A. Inhibition of Wnt signaling pathway by a novel Axin-binding protein. J Biol Chem. 2000;275:37030–7.PubMedCrossRef
49.
Cliffe A, Hamada F, Bienz M. A role of Dishevelled in relocating axin to the plasma membrane during wingless signaling. Curr Biol. 2003;13:960–6.PubMedCrossRef
50.
Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3ß regulates its stability. J Biol Chem. 1999;274:10681–4.PubMedCrossRef
51.
Zhang Y, Neo SY, Wang X, Han J, Lin SC. Axin forms a complex with MEKK1 and activatesc-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J Biol Chem. 1999;274:35247–54.PubMedCrossRef
52.
Luo W, Ng WW, Jin LH, Ye Z, Han J, Lin SC. Axin utilizes distinct regions for competitive MEKK1 and MEKK4 binding and JNK activation. J Biol Chem. 2003;278:37451–8. Axin: a master scaffold for multiple signaling pathways neurosignals 2004;13:99–113 111.PubMedCrossRef
53.
Kusano S, Raab-Traub N. I-mfa domain proteins interact with Axin and affect its regulation of the Wnt and c-Jun N-terminal kinase signaling pathways. Mol Cell Biol. 2002;22:6393–405.PubMedCrossRef
54.
Yamazaki H, Nusse R. Identification of DCAP, a Drosophila homolog of a glucose transport regulatory complex. Mech Dev. 2002;119:115–9.PubMedCrossRef
55.
Cowan CA, Henkemeyer M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature. 2001;413:174–9.PubMedCrossRef
56.
Zhang Y, Qiu WJ, Liu DX, Neo SY, He X, Lin SC, Lin SC. Differential molecular assemblies under liethe dual function of Axin in modulating theWnt and JNK pathways. J Biol Chem. 2000;276:32152–9.CrossRef
57.
Zhang Y, Neo SY, Han J, Lin SC. Dimerization choices control the ability of Axin and disheveled to activate c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem. 2000;275:25008–14.PubMedCrossRef
58.
Zhang Y, Qiu WJ, Chan SC, Han J, He X, Lin SC. Casein kinase I and casein kinase II differentially regulate Axin function in Wnt and JNK pathways. J Biol Chem. 2002;277:17706–12.PubMedCrossRef
59.
Rui HL, Fan E, Zhou HM, Xu Z, Zhang Y, Lin SC. SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling. J Biol Chem. 2002;277:42981–6.PubMedCrossRef
60.
Lustig BJ, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129:199–221.PubMed
61.
62.
Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–71.PubMedCrossRef
63.
Chakrabarty S, Fan D, Varani J. Modulation of differentiation and proliferation in human colon carcinoma cells by transforming growth factor beta 1 and beta 2. Int J Cancer. 1990;46:493–9.PubMedCrossRef
64.
Derynck R, Zhang Y, Feng X-H. Smads: transcriptional activators of TGF-b responses. Cell. 1998;95:737–40.PubMedCrossRef
65.
Miyazono K, ten Dijke P, Heldin C-H. TGF-b signaling by Smad proteins. Adv Immunol. 2000;75:115–57.PubMedCrossRef
66.
Pierreux CE, Nicola′s FJ, Hill CS. Transforming growth factor b-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol. 2000;20:9041–54.PubMedCrossRef
67.
Xiao Z, Liu X, Lodis HF. Importin b mediates nuclear translocation of Smad 3. J Biol Chem. 2000;275:23425–8.PubMedCrossRef
68.
Miura S, Takeshita T, Asao H, Kimura Y, Murata K, Sasaki Y, Hanai JI, Beppu H, Tsukazaki T, Wrana JL, Miyazono K, Sugamura K. Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol Cell Biol. 2000;20:9346–55.PubMedCrossRef
69.
Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFb receptor. Cell. 1998;95:779–91.PubMedCrossRef
70.
Dong C, Li Z, Alvarez R Jr, Feng X-H, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGFb activity. Mol Cell. 2000;5:27–34.PubMedCrossRef
71.
Ikeda S, Kishida M, Matsuura Y, Usui H, Kikuchi A. GSK-3b-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by b-catenin and protein phosphatase 2A complexed with Axin. Oncogene. 2000;19:537–45.PubMedCrossRef
72.
Massague J, Blain SW, Lo RS. TGFb signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309.PubMedCrossRef
73.
Hoosein NM, McKnight MK, Levine AE, Mulder KM, Childress KE, Brattain DE, Brattain MG. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Exp Cell Res. 1989;181:442–53.PubMedCrossRef
74.
Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:549–54.PubMed
75.
Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 1996;74:753–8.PubMedCrossRef
76.
Sheng H, Shao J, O’Mahony CA, Lamps L, Albo D, Isakson PC, Berger DH, DuBois RN, Beauchamp RD. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene. 1999;18:855–67.PubMedCrossRef
77.
Schroy P, Rifkin J, Coffey RJ, Winawer S, Friedman E. Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. Cancer Res. 1990;50:261–5.PubMed
78.
Claire RW, Roger JD. The JNK signal transduction pathway. Curr Opin Genet Dev. 2002;12:14–21.CrossRef
79.
80.
Zhang Y, Qiu WJ, Liu DX, Neo SY, He X, Lin SC. Differential molecular assemblies under liethe dual function of Axin in modulating the Wnt and JNK pathways. J Biol Chem. 2001;276:32152–9.PubMedCrossRef
81.
Webster MT, Rozycka M, Sara E, et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer. 2000;28:443–53.PubMedCrossRef
82.
Bellamy CO, Malcomson RD, Harrison DJ, et al. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol. 1995;6:3–16.PubMedCrossRef
83.
Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 2001;61:8247–55.PubMed
84.
Domingo E, Espin E, Armengol M, et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer. 2004;39:138–42.PubMedCrossRef
85.
Li-Hua JIN, Qiu-Jie SHAO, Wen LUO, Zhi-Yun YE, Qing LI and Sheng-Cai. LIN1, detection of point mutations of the axin1 gene in colorectal cancers. Int. J Cancer. 2003;107:696–99.
86.
Marie-Therese W, Magdalena R, Elizabeth S, Elaine D, Matthew S, Neville Y. Sequence Variants of the Axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding chromosomes & cancer 2000;28:443–453.
87.
Soichi I, Wataru K, Chie K, Shigeki A, Mitsuhiro N, Yoshiaki Y. Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:773–82.CrossRef
Metadata
Title
Diversity of axin in signaling pathways and its relation to colorectal cancer
Authors
Nighat Parveen
Mahboob Ul Hussain
Arshad A. Pandith
Syed Mudassar
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9722-x

Other articles of this Special Issue 1/2011

Medical Oncology 1/2011 Go to the issue

Original Paper

Antitumor efficacy of a photodynamic therapy-generated dendritic cell glioma vaccine

Original Paper

ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer

Original paper

CIDE-3 interacts with lipopolysaccharide-induced tumor necrosis factor, and overexpression increases apoptosis in hepatocellular carcinoma

Original Paper

Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases

Original Paper

Protective effect of l-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats

Original Paper

Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits